
Abstract

The invention relates to compounds of the general formula



I

wherein

R^1 is C_{6-12}-cycloalkyl, optionally substituted by lower alkyl or C(O)O lower alkyl, indan-1-yl or indan-2-yl, optionally substituted by lower alkyl; acenaphthen-1-yl; bicyclo[3.3.1]non-9-yl, octahydro-inden-2-yl; 2,3-dihydro-1H-phenalen-1-yl; 2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl, decahydro-azulen-2-yl; bicyclo[6.2.0]dec-9-yl; decahydro-naphthalen-1-yl, decahydro-naphthalen-2-yl; tetrahydro-naphthalen-1-yl, tetrahydro-naphthalen-2-yl or 2-oxo-1,2-diphenyl-ethyl;

R^2 is =O or hydrogen,

R^3 is hydrogen, isoindolyl-1,3-dione, lower alkoxy, lower alkyl, amino, benzyloxy, $-CH_2OR^5$ or $-CH_2N(R^5)_2$;

R^4 is hydrogen or $-CH_2OR^5$;

R^5 is hydrogen or lower alkyl;

(A) is cyclohexyl or phenyl, optionally substituted by lower alkyl, halogen or alkoxy;

to racemic mixtures and their corresponding enantiomers and or pharmaceutically acceptable acid addition salts thereof.

The compounds of the present invention are agonists and/or antagonists of the orphamin FQ (OFQ) receptor and therefore useful in the treatment of diseases, related to this receptor.

This Sheet Has Been Replaced



990306 6- 0